AstraZeneca introduced in the present day eight winners of the 2023 R&D Postdoctoral Problem and agreed to fund their postdoctoral positions at one of many Firm’s strategic R&D facilities in both Cambridge, UK, Gaithersburg or Boston, US or Gothenburg, Sweden.

The R&D Postdoctoral Problem stands out amongst conventional trade postdoctoral initiatives which often supply pre-defined initiatives. The distinctive program from AstraZeneca, now working for a second yr, permits early-career scientists from anyplace on this planet to submit and probably pursue their very own novel analysis proposals throughout the Firm. With the assist of extremely expert and multidisciplinary analysis groups, the winners will pursue their distinctive analysis initiatives to finally speed up drug discovery for among the world’s most advanced uncommon and continual ailments. By encouraging numerous considering and world collaboration, AstraZeneca pushes the boundaries of science to ship life-changing medicines.

After being short-listed from almost 100 candidates, eight finalists introduced their analysis proposals in a dwell occasion at AstraZeneca’s Discovery Centre (DISC), situated in Cambridge, UK. After presenting to a judging panel comprising AstraZeneca and exterior life science leaders, the winners had been chosen based mostly on scientific benefit and potential to create an actual affect for sufferers.

I used to be captivated by the pitches and seeing the novel approaches that each one of many finalists introduced on stage. However much more than that, I used to be impressed by their enthusiasm and fervour for his or her focus space of science, and their dedication to analysis that may enhance outcomes for sufferers.”

Dr Jenni Nordborg, Director, Worldwide Affairs, Lif

Dr Sharon Barr, Govt Vice President, BioPharmaceuticals R&D, AstraZeneca, mentioned: “Scientific progress depends upon our capacity to foster a group that encourages new concepts and contemporary views from the following technology of main scientists. We’re thrilled to welcome the eight winners to AstraZeneca; this distinctive program demonstrates our dedication to supporting early expertise and science led innovation.”

Dr Seng Cheng, Senior Vice President, Analysis and Product Improvement, Alexion, mentioned: “The winners are all united by their willingness to step away from the norm and pursue a program that’s utterly altering the normal postdoc scheme. They convey the fervour and enthusiasm to innovate, as effectively a collective ambition to speed up drug discovery.”

With absolutely funded AstraZeneca postdoctoral analysis positions, the winners achieve entry to the Firm’s experience, compounds, novel instruments and applied sciences, in addition to mentoring assist to show their revolutionary concepts into options that would profit sufferers all over the world.

As a part of AstraZeneca’s Early Expertise packages, the R&D Postdoctoral Problem helps the dedication to early profession scientists by nurturing expertise and offering alternatives to work inside a various and inclusive setting that allows science to thrive.